Marilena A. Di Napoli
Naples, 80131, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications
Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network.
Journal: Current oncology (Toronto, Ont.)
Published: April 22, 2026
Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33-REGAL study.
Journal: Therapeutic advances in medical oncology
Published: January 26, 2026
Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).
Journal: BMC cancer
Published: January 20, 2026
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study.
Journal: Cancer immunology, immunotherapy : CII
Published: October 24, 2025
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24).
Journal: European urology open science
Published: September 28, 2025
The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective.
Journal: Frontiers in immunology
Published: July 07, 2025
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 08, 2024
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study.
Journal: Cancer immunology, immunotherapy : CII
Published: February 25, 2024
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study.
Journal: Clinical genitourinary cancer
Published: January 08, 2024
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.
Journal: Frontiers in immunology
Published: December 24, 2023
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab.
Journal: JAMA network open
Published: November 27, 2023
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study.
Journal: Frontiers in oncology
Published: October 23, 2023
Last Updated: 09/26/2026